Lead Poisoning
Clinical Snapshot
Lead poisoning is toxicity from accumulated exposure to lead, a naturally occurring heavy metal with no known biological function in the human body and, according to the weight of current evidence, no threshold blood level below which it is genuinely safe — a point Canadian paediatric guidance states explicitly rather than as a hedge.[1] Lead interferes with normal physiology through two overlapping mechanisms: it binds avidly to sulfhydryl and other electron-donor groups on proteins throughout the body, and it mimics divalent cations — calcium and zinc in particular — letting it intrude into calcium-dependent processes it has no business being part of, including synaptic development in a growing brain.[2] Its single most consequential and clinically useful target is haem synthesis: lead inhibits several of the enzymes that build haem, which both starves red cells of functional haemoglobin — producing a microcytic or normocytic anaemia — and leaves behind the coarse basophilic stippling that is a classic, genuinely useful clue on a peripheral blood smear (see Assessment & Diagnosis).[2]
Once absorbed, lead settles into two body compartments with very different kinetics, and this split explains almost everything about how this disease is actually managed. In blood, its half-life is on the order of weeks. In bone — where the great majority of the body's total lead burden ultimately resides, roughly 85-95% in an adult and a somewhat smaller share, around 70%, in a child, whose remaining burden instead sits in more metabolically active soft tissue (liver, kidney, bone marrow, brain) — lead persists for years to decades, acting as a slow-release internal reservoir that can re-elevate blood lead long after an external source has been fully controlled, and that chelation itself can inadvertently mobilize.[2] This is exactly why source identification and removal, not any pharmacologic agent, is the true foundation of treatment in every section of this chapter, and why chelation is discussed throughout as a threshold-based adjunct rather than a cure.
Two clinical pictures matter, and they call for genuinely different urgency. Frank, high-dose acute poisoning producing encephalopathy, seizures, or coma is now rare in Canadian practice and is a medical emergency the moment it is suspected. Far more common — and far more likely to be missed entirely — is chronic, low-level exposure that produces no distinctive symptoms at all, particularly in children, where blood lead concentrations that measurably reduce IQ and academic achievement routinely cause nothing a caregiver or clinician would notice without specifically testing for it.[2][1] This chapter covers both, but its centre of gravity is deliberately the low-level, insidious, easily-missed picture, since that is what a community pharmacist is actually likely to encounter — most often as a risk-factor conversation or a screening result, not a poisoning "event."
Recognize the Condition
Chronic, low-level exposure — the presentation that matters most in practice
The great majority of lead exposure encountered in Canadian primary care and community pharmacy today is chronic and low-level, and it is subtle almost by definition. In children, it is very often entirely asymptomatic and is discovered only through targeted screening in a child with a recognized risk factor (see Risk Factors), not through a specific complaint that prompts testing on its own.[1] When something is noticed, it tends to be nonspecific — irritability, a "difficult" temperament, inattention, hyperactivity, subtle developmental delay, or falling behind academically — findings that are genuinely easy to attribute to a hundred other, more common explanations.[2] A specific and counterintuitive point worth knowing: the dose-response relationship between blood lead concentration and IQ loss is steeper at lower blood lead concentrations than at higher ones, meaning a rise from roughly 1 to 10 µg/dL costs a child more IQ points than an equivalent rise from 10 to 20 µg/dL — so there is no meaningfully "safe" low range to reassure a worried caregiver about.[2]
Acute, high-dose exposure
Acute poisoning at high blood lead concentrations produces a more recognizable, and more dangerous, picture. In children, this can progress to lead encephalopathy — unusual behaviour, developmental regression, ataxia, vomiting, seizures, and in severe cases cerebral oedema with raised intracranial pressure, coma, and death — a true paediatric emergency, typically occurring at blood lead concentrations above roughly 70-100 µg/dL, though it can occur at lower levels in a young child.[2] In adults, the classic picture is different, and is easy to miss entirely if it is not specifically considered: colicky, poorly localized abdominal pain ("lead colic"), constipation, anorexia, headache, fatigue, and myalgia or arthralgia, sometimes together with a motor-predominant peripheral neuropathy — classically wrist drop, or less often foot drop — reflecting lead's relatively selective effect on fast-conducting motor axons.[3][2] Severe adult toxicity can also produce cognitive and mood change and, at the extreme, adult encephalopathy with confusion, seizures, and obtundation.[3]
Two classic bedside findings — worth knowing, rarely diagnostic
A Burton's line — a thin blue-grey line at the gingival margin from lead sulfide deposition, seen mainly with poor oral hygiene and substantial chronic exposure — and the wrist/foot drop described above are both genuine, classically taught findings. Both are also late and insensitive, dating from an era before blood lead testing was routinely available. A normal examination never excludes clinically important lead exposure; a confirmed blood lead level, not the physical exam, is what actually makes or excludes this diagnosis (see Assessment & Diagnosis).
Saturnine gout — a genuinely useful adult clue
Chronic lead exposure impairs renal tubular urate handling, producing hyperuricemia and, in some patients, a secondary gout historically termed "saturnine gout" that can be the presenting complaint in an adult with an otherwise unremarkable history.[2] New or atypical gout — particularly without the usual metabolic risk factors, or in a patient with any plausible occupational or hobby lead exposure — is worth a specific, direct question about lead exposure rather than being treated purely as primary gout.
Risk Factors
- Age under 6 years, and especially 1-3 years — the age of peak hand-to-mouth behaviour and the highest gastrointestinal lead absorption (children absorb roughly 40-50% of ingested lead, versus roughly 10-15% in adults).[2]
- Housing built before 1960, or renovation, remodelling, or demolition of any older home — lead-based paint was used extensively in Canadian housing before that period, and dust generated by sanding, scraping, or demolition is a more important exposure route than intact painted surfaces.[1]
- Homes with lead water service lines or lead-soldered plumbing — lead pipe was installed in Canada up to roughly 1960, and lead solder in plumbing continued to be used into the 1980s.[1]
- Pica, or any history of mouthing or eating non-food items, including paint chips.[1]
- A sibling, playmate, or other household or daycare contact with a known history of an elevated blood lead level — implies a shared environmental source that has not yet been found.[1]
- Newcomers to Canada, including internationally adopted children, particularly from regions with higher population-level lead exposure.[1]
- Imported consumer goods: costume jewellery, painted toys, ceramics and glazed pottery (including food or drink stored or served in leaded ceramics, pewter, or leaded crystal glassware), and candles with a metal-core wick.[1]
- Imported cosmetics, particularly traditional kohl, kajal, or surma products — Health Canada has specifically identified and advised against products from multiple countries of origin after Canadian children using them were found with elevated blood lead levels.[4]
- Traditional or folk remedies, including some imported preparations, that fall outside Canadian manufacturing and lead-content standards.
- Indigenous communities whose traditional diet can include meat from animals harvested with lead ammunition — a specific, genuinely Canadian risk factor named directly in Canadian paediatric guidance.[1]
- Iron, calcium, or zinc deficiency — each independently increases gastrointestinal lead absorption, and lead ingested on an empty stomach is absorbed considerably more efficiently than lead taken in with food.[2]
- Occupational exposure: battery manufacturing and recycling, secondary lead smelting, radiator repair, construction and demolition of older structures, bridge and structural-steel work, firing-range instruction, and stained-glass or pottery-glazing work.[5]
- Hobby and avocational exposure: home firing ranges, ammunition reloading, fishing-weight or sinker casting, stained glass, and some ceramics or pottery work.[5]
- A retained bullet fragment from a firearm injury, particularly a fragment lying within a joint space or disc space, or in contact with synovial or cerebrospinal fluid.[6]
- Pregnancy — lead stored for years in maternal bone from lifetime exposure is mobilized by the physiologic bone turnover of pregnancy and lactation, re-entering the maternal (and, across the placenta, fetal) circulation even without any new external exposure.[2]
Red Flags & Refer
Refer promptly — treat as an emergency-department/poison-control matter for the items below marked as such:
- Any sign of encephalopathy at any age — altered behaviour, developmental regression, ataxia, vomiting, seizures, or altered consciousness — regardless of whether a blood lead result is back yet. This is a medical emergency; do not wait for confirmatory testing before arranging urgent assessment.[2]
- A confirmed paediatric venous blood lead level over 44 µg/dL — consult the regional Poison Control Centre and consider hospitalization and chelation.[1]
- An adult blood lead level of roughly 70-100 µg/dL or higher, or any adult with symptoms of significant toxicity (colic, motor neuropathy, cognitive change) regardless of the exact confirmed level.[3]
- Any pregnant patient with a confirmed blood lead level of 5 µg/dL or higher — counsel on exposure avoidance at minimum, and involve toxicology and high-risk obstetrics directly for a level of 45 µg/dL or higher.[7][8]
- A retained bullet fragment together with a rising blood lead level, new symptoms, or a fragment located in a joint space, intervertebral disc space, or in contact with cerebrospinal or synovial fluid.[6]
- More than one child in the same household, daycare, or play group with an elevated blood lead level — this is an environmental problem, not only an individual medical one; involve public health to investigate the shared source rather than managing each child in isolation.[1]
- New, unexplained gout, a motor-predominant peripheral neuropathy (especially wrist or foot drop), or unexplained abdominal colic in an adult with any plausible occupational or hobby lead exposure.[2]
Assessment & Diagnosis
The test that actually makes the diagnosis
A venous blood lead level is the test that establishes the diagnosis and drives every management decision in this chapter. A capillary (fingerstick) sample is acceptable for initial screening because it is simple and inexpensive, but any elevated capillary result must be confirmed with a venous sample before acting on it — capillary sampling carries a genuine risk of surface lead contamination producing a falsely elevated result.[5][2]
Peripheral blood smear
Coarse basophilic stippling of red blood cells — aggregates of degraded ribosomal RNA that a lead-inhibited enzyme normally clears — is a classic and genuinely useful incidental clue, sometimes the first hint of lead poisoning in a patient whose blood film was drawn for an entirely different reason (unexplained anaemia, a general work-up).[2]
Supporting laboratory investigations
- Complete blood count and iron studies (ferritin) — lead-associated anaemia is typically microcytic or normocytic, and coexisting iron deficiency is common and clinically important, since it both worsens the anaemia and independently increases gastrointestinal lead absorption (see Treatment Targets).[2]
- Renal function (serum creatinine, eGFR) — chronic lead exposure causes proximal tubular (Fanconi-like) dysfunction and, over time, chronic lead nephropathy; baseline renal function also directly informs chelator selection and dosing.[2][5]
- Erythrocyte/zinc protoporphyrin (ZPP or free erythrocyte protoporphyrin) — reflects lead's inhibition of the enzyme ferrochelatase and was historically used for occupational surveillance; it is an insensitive screening test at lower blood lead concentrations and should never substitute for a direct blood lead measurement, though it remains a reasonable adjunct in some occupational programs.[2]
- Abdominal X-ray in a young child with a pica history or suspected acute ingestion of a lead-containing object (a paint chip, a fishing weight, a curtain weight, a foreign body) — radiopaque material may be visible and, if present, directly changes management (see Non-Pharmacologic Treatment).[2]
- Long-bone X-ray (wrist or knee) showing dense metaphyseal bands — the classically taught "lead lines" — reflects substantial chronic paediatric exposure during a period of active bone growth. It is rarely needed for diagnosis now that direct blood lead testing is routinely available, but can support the diagnosis or help resolve genuine diagnostic uncertainty in an unusual case.
Differential diagnosis
In a child: iron deficiency anaemia (which commonly coexists with, rather than substitutes for, lead exposure), primary attention-deficit or behavioural disorders, other causes of developmental delay, and other heavy-metal exposures (arsenic, mercury). In an adult: carpal tunnel syndrome or another compressive/entrapment neuropathy (versus lead's characteristically motor-predominant peripheral neuropathy), primary gout, irritable bowel syndrome or another cause of chronic abdominal pain, porphyria, and other causes of a microcytic or normocytic anaemia with basophilic stippling (thalassemia, sideroblastic anaemia).[2]
Treatment Targets
- Identify and eliminate — or, where full elimination is not immediately possible, substantially reduce — the source of ongoing exposure. This is the single most important treatment target in this entire chapter and takes priority over every pharmacologic decision below.
- Confirm any elevated screening or capillary result with a venous blood lead level before acting on it.
- Correctly tier management to the confirmed blood lead level and clinical picture, escalating to chelation only once a defined threshold or encephalopathy is met — not before, and never as a substitute for source control.
- Correct coexisting iron, calcium, or zinc deficiency, which both worsens lead-associated anaemia and independently increases ongoing gastrointestinal lead absorption.
- Prevent — or, in a genuine emergency, treat — lead encephalopathy and its neurologic sequelae.
- Set realistic, honest expectations: in an asymptomatic child, current evidence does not show that reducing exposure — let alone chelation — reverses neurodevelopmental injury already sustained, which is exactly why prevention and early detection matter more than any treatment offered after the fact.[2]
- In pregnancy, minimize ongoing fetal lead exposure while recognizing that chelation itself carries real, largely avoidable maternal-fetal risk and is reserved for a genuine emergency rather than a routine response to an elevated level (see Special Populations).
- Arrange environmental investigation, cascade screening of other at-risk household or daycare contacts, and appropriate public health notification.
Choose Initial Treatment
Source removal first, for every patient, at every blood lead level
Regardless of the confirmed level, identifying and removing the source of exposure is the first action for every patient — not something arranged after chelation is decided, and not something a course of chelation can substitute for. Chelation is adjunctive, threshold-based, and, outside of encephalopathy, is never a first-reflex response to an elevated result.[1]
Children — the Canadian blood-lead-level action tiers
| Confirmed venous blood lead level | Recommended action |
|---|---|
| 5-14 µg/dL | Review the result with the family; complete a neurodevelopmental screen and a nutritional assessment (iron, calcium, zinc adequacy); complete a paediatric environmental health history; contact public health to help identify the source; retest in 1-3 months. |
| 15-44 µg/dL | All of the above, plus confirm with a repeat venous sample within 1-4 weeks; consider an abdominal X-ray if the history suggests recent ingestion of a lead-containing object. |
| Over 44 µg/dL | All of the above, plus consult the regional Poison Control Centre and consider hospitalization and chelation; confirm with repeat venous testing at 48 hours. |
[1] Chelation is only indicated at genuinely high blood lead levels and must be directed by, or undertaken in direct consultation with, a physician experienced in lead chelation therapy — it is not a routine response to most of the 15-44 µg/dL range.[1]
Adults, including occupational exposure
For a worker with occupational lead exposure, remove from further lead exposure once a single blood lead level reaches 30 µg/dL, or once two levels measured roughly 4 weeks apart both reach 20 µg/dL or higher. Sustained levels below 10 µg/dL still warrant semiannual medical surveillance, and levels of 10-19 µg/dL warrant quarterly surveillance together with a review of workplace exposure controls.[7] Chelation in adults is reserved for genuinely symptomatic, highly exposed patients — it is not recommended for an asymptomatic adult with a low or moderately elevated blood lead level — and becomes a clear priority once the level reaches roughly 70-100 µg/dL, or immediately, regardless of the exact level, if there is any sign of encephalopathy.[7][3][2]
Chelation agent selection by severity
- Children, 45-69 µg/dL, no encephalopathy: oral succimer (DMSA) as the primary agent.[3][9]
- Children or adults, 70 µg/dL or higher, or any encephalopathy at any level: combined parenteral therapy — dimercaprol (BAL) started first, with calcium disodium EDTA added roughly 4 hours later, continued together for about 5 days. Calcium EDTA should not be given as monotherapy at a very high blood lead level or with encephalopathy present, since without dimercaprol on board first it can acutely mobilize lead from bone into blood and the central nervous system and worsen the clinical picture.[3][9]
Full dosing, adverse effects, and monitoring for each agent are in Drug Tables.
Non-Pharmacologic Treatment
Source identification and remediation
- Complete a detailed exposure history covering housing age and any recent renovation, water source and plumbing age, occupation and hobbies of every household member, imported consumer products and cosmetics, folk or traditional remedies, and diet (including traditional foods and any game harvested with lead ammunition).[1][5]
- Involve public health/environmental health for a home (or workplace) investigation whenever a source is not already obvious — this is genuinely a team effort, not something the prescribing or dispensing clinician is expected to run alone.[1]
- For lead-based paint: professional abatement using wet methods (never dry sanding or scraping, which aerosolizes lead dust); relocate the household, especially young children, during active remediation.
- For lead plumbing: identify and, where feasible, replace lead service lines or lead-soldered fixtures; in the interim, run cold water to flush the line before use for drinking or cooking, and use a filter independently certified to reduce lead.
- Discontinue use of any identified offending consumer product, cosmetic, or remedy immediately, and counsel the family not to simply store it "for later" — remove it from the home.
Nutritional optimization
Ensure adequate dietary iron, calcium, and zinc — deficiency in any of these independently increases gastrointestinal lead absorption, and regular meals (rather than a fasting state) further reduce the fraction of ingested lead that is actually absorbed.[2] Correcting a confirmed iron deficiency is a genuine, evidence-based part of management in its own right, not only a general wellness recommendation (see Pharmacologic Treatment Options).
Hygiene and household measures
- Regular handwashing before meals and snacks, and after outdoor play, particularly for a young child with any pica behaviour.
- Wet-mopping and wet-dusting rather than dry sweeping in a home with any suspected lead-dust source, since dry methods redistribute dust rather than removing it.
- Remove shoes at the door to reduce tracking of lead-contaminated soil indoors, particularly near a home with exterior lead paint or in an area with known soil contamination.
Occupational controls
Engineering controls (ventilation, wet methods to suppress dust), appropriate respiratory protection and other personal protective equipment, on-site handwashing and changing facilities separate from break areas, and not permitting food, drink, or smoking in a lead work area are all standard measures; occupational lead exposure limits and medical surveillance requirements are set provincially in Canada, so confirm the specific requirements that apply to the worker's jurisdiction and workplace.[5]
Cascade and household screening
Offer blood lead testing to every other child in the same household, daycare, or play group as an index case, and to other household members sharing the same environmental source — a single elevated result should prompt looking beyond the one patient in front of you.[1]
Special Populations
Pregnancy
Roughly 70% of the total lead in an adult body sits in bone, and the physiologic bone turnover of pregnancy mobilizes some of that stored lead back into the maternal circulation — and, across the placenta, into the fetal circulation — even without any new external exposure.[2] Counsel every pregnant patient on exposure avoidance once the blood lead level reaches 5 µg/dL, and manage in direct consultation with toxicology and high-risk obstetrics once it reaches 45 µg/dL.[7][8] Chelation in pregnancy is generally avoided — all three chelators have reported teratogenic effects in animal studies, particularly in the first trimester, and chelation itself risks mobilizing additional lead from maternal bone into an already-exposed fetal circulation — and is reserved for a genuine maternal emergency (very high blood lead level or encephalopathy) rather than used on the strength of an elevated level alone.[8]
Lactation
A woman with a blood lead level under 40 µg/dL can be encouraged to initiate and continue breastfeeding. At 40 µg/dL or higher, advise pumping and discarding breast milk until the level has fallen below that threshold, since lead does transfer into breast milk, though to a materially lesser degree than the transplacental route active during pregnancy.[8]
Children
The population this chapter is centred on — see Recognize the Condition, Risk Factors, and Choose Initial Treatment for the full paediatric pathway. Peak absorption and peak exposure both occur in the toddler years, and the asymptomatic, low-level presentation is the norm rather than the exception.
Retained bullet fragments
Lead fragments retained after a firearm injury are a recognized, likely under-recognized source of chronic lead exposure; U.S. national surveillance data have documented elevated blood lead levels specifically associated with retained bullet fragments.[6] A reasonable approach is blood lead screening for at least the first year after the injury, with surgical removal generally reserved for a fragment in a joint space, an intervertebral disc space, in contact with cerebrospinal or synovial fluid, causing nerve impingement, or associated with a rising blood lead level or new symptoms despite conservative management — not for retained fragments in general, most of which are left in place.[6]
Renal impairment
Chronic lead exposure itself causes progressive renal injury, and calcium EDTA is independently nephrotoxic, so baseline and on-treatment renal function should directly inform both chelator choice and dose in any patient with pre-existing renal impairment; involve nephrology for a patient with significant baseline renal disease being considered for chelation.[2]
G6PD deficiency and peanut allergy
Dimercaprol is formulated in peanut oil and is contraindicated in peanut allergy, and it carries a risk of haemolysis in G6PD deficiency — confirm both before use, particularly since dimercaprol is used specifically in the sickest patients, where a delay to confirm this is a genuine practical tension against the urgency of severe poisoning or encephalopathy.
Occupational and hobby-exposed adults
See Choose Initial Treatment for the specific removal and surveillance thresholds. Occupational lead exposure limits and medical surveillance requirements are set provincially in Canada; confirm the specific requirements that apply to a given worker's jurisdiction and workplace rather than assuming a single national standard.[5]
Monitoring & Follow-Up
Retesting by tier
Follow the same interval used to guide initial action: retest in 1-3 months for a level of 5-14 µg/dL; confirm with a repeat venous sample in 1-4 weeks for 15-44 µg/dL; confirm with repeat venous testing at 48 hours for a level over 44 µg/dL.[1]
Post-chelation rebound testing
Because bone stores continue releasing lead back into blood after a chelation course ends, recheck the blood lead level roughly 1-2 weeks after completing chelation to detect rebound elevation, rather than assuming the end-of-course level represents the durable result.[3][9] A meaningful rebound, especially if the source has genuinely been controlled, may warrant a further chelation course after an interval — see Treatment Failure/Next Step.
During active chelation
- Complete blood count, renal function, and (for calcium EDTA) urinalysis at baseline and periodically during therapy.[3]
- Liver enzymes periodically during succimer therapy, given its association with transient transaminase elevation.
- Clinical reassessment for evolving neurologic signs at every visit during active treatment of severe poisoning or encephalopathy.
Longer-term follow-up
- Serial developmental and academic screening for any child with a history of an elevated blood lead level, continued even after the level has normalized, since damage already sustained may not be evident or fully reversible on a single follow-up visit.[2]
- Confirm — do not simply assume — that identified remediation (paint abatement, plumbing replacement, product removal, occupational control changes) has actually been completed, and retest the environment (water, dust wipe) where relevant.
- Confirm cascade screening of other at-risk household, daycare, or workplace contacts has been completed, not only offered once and left open.
Common Errors to Avoid
- Treating chelation as a substitute for source removal, rather than as an adjunct — chelating a patient back into an unremediated environment invites ongoing exposure and rebound elevation.
- Acting on an elevated capillary (fingerstick) result without confirming it with a venous sample first — capillary sampling carries a genuine risk of surface contamination and a false positive.[5]
- Reassuring a family that a "mildly" elevated paediatric blood lead level (for example, in the 5-14 µg/dL range) is not a concern — there is no evidence-based safe threshold, and the dose-response curve for IQ loss is actually steepest at these lower levels.[2]
- Starting chelation for an asymptomatic, low-to-moderately elevated result instead of the source-identification, nutrition, and monitoring pathway that is actually indicated at that tier.[1]
- Giving calcium EDTA as monotherapy in a patient with a very high blood lead level or encephalopathy, without dimercaprol first — this can acutely mobilize bone lead into blood and the central nervous system and worsen the clinical picture.[3]
- Missing the diagnosis in an adult because the presentation (fatigue, myalgia, abdominal pain, mood change) is nonspecific and no one has asked about occupational or hobby lead exposure.[3]
- Not specifically asking about imported cosmetics, imported toys or jewellery, folk or traditional remedies, or traditional foods that may include lead-ammunition-harvested game.[1][4]
- Forgetting cascade screening of siblings, other daycare or play-group children, or co-workers of an index case.[1]
- Not specifically counselling a pregnant or breastfeeding patient, or applying the general adult thresholds to her instead of the materially lower, pregnancy/lactation-specific ones.[8]
- Discharging a chelated patient without arranging rebound testing 1-2 weeks later, or assuming the end-of-course level is the durable result.[3]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are typical reported regimens and require patient-specific confirmation (renal/hepatic function, weight, allergy history, pregnancy status) and, for every chelator, specialist or Poison Control Centre direction before use. None of the three chelating agents below has a Pharmasist Drug Database monograph page, so each renders as plain text; penicillamine, ferrous sulfate, calcium carbonate, diazepam, and mannitol do, and are linked. Chelation is always an adjunct to — never a substitute for — identifying and removing the actual source of exposure.
Oral Chelation
For children with a confirmed blood lead level of 45-69 µg/dL and no encephalopathy, or as a rarely-used oral alternative when preferred agents are unavailable or not tolerated.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Succimer (DMSA) | Regimen: 10 mg/kg (or 350 mg/m²) PO every 8 hours for 5 days, then every 12 hours for an additional 14 days | Gastrointestinal upset, a characteristic sulfurous ('rotten egg') odour to the patient's breath/urine, transient elevation of liver transaminases, neutropenia (rare) | None clinically significant at standard dosing | Primary oral chelator for moderate paediatric poisoning. Only started once the source has genuinely been addressed — starting chelation into an unremediated home invites ongoing exposure and blunts the treatment response.[3][9] |
| Penicillamine | Use in lead poisoning: Specialist-directed, off-label dosing | Gastrointestinal upset, skin rash, rare but serious blood dyscrasias (requires monitoring), proteinuria, cross-sensitivity in penicillin allergy | Reduced absorption with antacids and iron salts — separate dosing by at least 2 hours | Not officially approved for lead poisoning; used off-label as a third-line oral option, generally at a lower dose than typical Wilson-disease dosing, when succimer and parenteral agents are genuinely unavailable or not tolerated. More adverse effects and less evidence than succimer. |
Parenteral Chelation — Severe Poisoning or Encephalopathy
For a confirmed blood lead level of 70 µg/dL or higher, or any degree of encephalopathy at any level. Hospital/ICU-level care; combined therapy, not either agent alone.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Dimercaprol (BAL) | Regimen: Approximately 75 mg/m² per dose (about 25 mg/kg/day) IM, divided into doses every 4 hours, for 2-5 days; the first dose precedes calcium EDTA by roughly 4 hours | Febrile reactions, nausea and vomiting, hypertension and tachycardia, sterile abscess at the injection site, haemolysis in G6PD deficiency | Avoid concurrent iron supplementation — dimercaprol-iron complexes are toxic; do not co-administer | Given first, before calcium EDTA, in severe poisoning or encephalopathy. Contraindicated in peanut allergy (the formulation is peanut-oil based) and used with caution in G6PD deficiency — confirm both before use, balanced against the urgency of severe presentations.[3][9] |
| Calcium disodium EDTA (edetate calcium disodium) | Regimen: 25-50 mg/kg/day (approximately 1000-1500 mg/m²/day) IV or IM, divided or as a continuous infusion, over 5 days | Nephrotoxicity (dose- and hydration-dependent), injection-site discomfort with IM administration, zinc depletion with prolonged use | Do not confuse with disodium EDTA (without calcium) — administering the wrong salt can cause fatal hypocalcemia | Never given as monotherapy at a very high blood lead level or with encephalopathy present — start only after or together with dimercaprol, since calcium EDTA alone can acutely mobilize bone lead into blood and the central nervous system. Ensure adequate hydration and monitor renal function and urinalysis during therapy.[3][9] |
Adjunctive and Supportive Therapy
Treat coexisting deficiency, seizures, and cerebral oedema alongside chelation and source removal — none of these agents chelate lead themselves.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ferrous sulfate (or another iron salt) | Use in lead poisoning: Per standard iron-deficiency-anaemia dosing, product-monograph-directed | Gastrointestinal upset, constipation (can overlap with lead-colic symptoms), dark stools | Reduces absorption of oral penicillamine and some other oral medications if co-administered — separate dosing | Reserve for a confirmed concurrent iron deficiency rather than empiric use; correcting deficiency both improves anaemia and reduces further gastrointestinal lead absorption. Avoid dosing at the exact same time as oral succimer. |
| Calcium carbonate | Use in lead poisoning: Per standard calcium-supplementation dosing, product-monograph-directed | Constipation, hypercalcemia with excessive intake | May reduce absorption of some concurrently administered oral medications | Ensuring adequate dietary or supplemental calcium intake is part of the nutritional-optimization approach that reduces ongoing gastrointestinal lead absorption, particularly in a child with confirmed dietary calcium insufficiency. |
| Diazepam | Use in lead poisoning: IV, per product monograph and local seizure/status-epilepticus protocol, titrated to effect | Sedation, respiratory depression, hypotension | Additive CNS/respiratory depression with other sedatives or opioids | For seizure termination in lead encephalopathy. A seizure in this context signals a true emergency — escalate to combined parenteral chelation and critical care rather than treating it as an isolated event. |
| Mannitol | Use in lead poisoning: IV, ICU/specialist-directed dosing | Electrolyte disturbance, volume depletion, rebound intracranial pressure elevation | Additive risk of electrolyte disturbance with other diuretics | Adjunctive ICU-level measure for cerebral oedema with raised intracranial pressure in the most severe presentations of lead encephalopathy, alongside chelation and airway/haemodynamic support. |
References
- Lead toxicity with a new focus: Addressing low-level lead exposure in Canadian children — Canadian Paediatric Society, Paediatric Environmental Health Section (Buka I, Hervouet-Zeiber C). Paediatr Child Health 2019;24(4):293, posted June 21, 2019
- Lead Toxicity — StatPearls, StatPearls Publishing, National Library of Medicine (Halmo L, Nappe TM). StatPearls [Internet], updated July 4, 2023
- Lead — Medical Management Guidelines — Agency for Toxic Substances and Disease Registry (ATSDR), U.S. Centers for Disease Control and Prevention. ATSDR Medical Management Guidelines (MMG)
- Health concerns about lead in traditional kohl — Health Canada. Government of Canada, Cosmetic Safety
- Clinical Evaluation for Lead Exposure: A Simplified Approach — Public Health Ontario. Public Health Ontario, July 25, 2024
- Elevated Blood Lead Levels Associated with Retained Bullet Fragments — United States, 2003-2012 — Morbidity and Mortality Weekly Report (MMWR), U.S. Centers for Disease Control and Prevention. MMWR 2017;66(5):130-133
- Recommendations for Medical Management of Adult Lead Exposure — Environmental Health Perspectives (Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz BS, Hu H, Woolf A). Environ Health Perspect 2007;115(3):463-471
- Committee Opinion No. 533: Lead Screening During Pregnancy and Lactation — American College of Obstetricians and Gynecologists (ACOG). Obstet Gynecol 2012;120(2):416-420
- Lightening the Lead Load in Children — American Family Physician (Ellis MR, Kane KY). Am Fam Physician 2000;62(3):545-554
- Risk Management Strategy for Lead — Health Canada. Government of Canada, Environmental and Workplace Health
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.